Raymond D Pratt

Summary

Affiliation: Eisai Medical Research
Country: USA

Publications

  1. ncbi request reprint Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia
    Raymond D Pratt
    Eisai Inc, Glenpointe Centre West, 500 Frank W Burr Blvd, Teaneck, NJ 07666 6741, USA
    J Neurol Sci 203:57-65. 2002
  2. ncbi request reprint Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits
    Raymond D Pratt
    Clinical Research, Eisai Incorporated, Glenpointe Centre West, 500 Frank W Burr Boulevard, Teaneck, NJ 07666 6741, USA
    Ann N Y Acad Sci 977:513-22. 2002
  3. ncbi request reprint Patient populations in clinical studies of donepezil in vascular dementia
    Raymond D Pratt
    Eisai Medical Research, Teaneck, New Jersey 07666, USA
    Int Psychogeriatr 15:195-200. 2003
  4. pmc Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses
    Josephine F Reyes
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgefield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:50-7. 2004
  5. pmc Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses
    Chukwuemeka S Okereke
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgefield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:41-9. 2004
  6. pmc Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses
    Christa F Nagy
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgfield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:25-33. 2004
  7. pmc Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function
    Christa F Nagy
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgefiled Park, NJ 07660, USA
    Br J Clin Pharmacol 58:18-24. 2004
  8. pmc Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients
    Josephine F Reyes
    Clinical Pharmacology, Eisai Medical Research Inc, Rigefield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:9-17. 2004
  9. ncbi request reprint Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials
    Anne Whitehead
    The University of Reading, Medical and Pharmaceutical Statistics Research Unit, Reading, UK
    Int J Geriatr Psychiatry 19:624-33. 2004
  10. ncbi request reprint Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study
    Larry Tune
    Wesley Woods Center at Emory University, Atlanta, GA, USA
    Am J Geriatr Psychiatry 11:169-77. 2003

Detail Information

Publications16

  1. ncbi request reprint Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia
    Raymond D Pratt
    Eisai Inc, Glenpointe Centre West, 500 Frank W Burr Blvd, Teaneck, NJ 07666 6741, USA
    J Neurol Sci 203:57-65. 2002
    ..These observations suggest that the patients enrolled in these trials have a broad range of CVD, and are different from those enrolled in AD trials...
  2. ncbi request reprint Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits
    Raymond D Pratt
    Clinical Research, Eisai Incorporated, Glenpointe Centre West, 500 Frank W Burr Boulevard, Teaneck, NJ 07666 6741, USA
    Ann N Y Acad Sci 977:513-22. 2002
  3. ncbi request reprint Patient populations in clinical studies of donepezil in vascular dementia
    Raymond D Pratt
    Eisai Medical Research, Teaneck, New Jersey 07666, USA
    Int Psychogeriatr 15:195-200. 2003
    ..There are difficulties in accurately defining patients with vascular dementia (VaD) and, therefore, little is known about the characteristics of this population...
  4. pmc Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses
    Josephine F Reyes
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgefield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:50-7. 2004
    ..This open-label, multiple-dose trial investigated the effect of concurrent administration of donepezil HCl with risperidone on the pharmacokinetics (PK) and safety profiles of both drugs...
  5. pmc Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses
    Chukwuemeka S Okereke
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgefield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:41-9. 2004
    ..This randomized, double-blind, crossover study investigated the safety of, and possible drug-drug interaction between, donepezil HCl and levodopa/carbidopa...
  6. pmc Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses
    Christa F Nagy
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgfield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:25-33. 2004
    ..This study evaluated the safety and pharmacokinetics (PK) of donepezil HCl and sertraline HCl when administered separately and in combination...
  7. pmc Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function
    Christa F Nagy
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgefiled Park, NJ 07660, USA
    Br J Clin Pharmacol 58:18-24. 2004
    ..To characterize the pharmacokinetic, pharmacodynamic and safety profiles of donepezil in subjects with moderate renal impairment and matched healthy controls during single-dose and multiple-dose phases...
  8. pmc Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients
    Josephine F Reyes
    Clinical Pharmacology, Eisai Medical Research Inc, Rigefield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:9-17. 2004
    ....
  9. ncbi request reprint Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials
    Anne Whitehead
    The University of Reading, Medical and Pharmaceutical Statistics Research Unit, Reading, UK
    Int J Geriatr Psychiatry 19:624-33. 2004
    ..The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD)...
  10. ncbi request reprint Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study
    Larry Tune
    Wesley Woods Center at Emory University, Atlanta, GA, USA
    Am J Geriatr Psychiatry 11:169-77. 2003
    ..The authors evaluated the effects of donepezil (10 mg/day) versus placebo on brain glucose metabolism...
  11. ncbi request reprint Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease
    William B Smith
    New Orleans Center for Clinical Research, Knoxville, Tennessee, USA
    Clin Ther 29:1368-80. 2007
    ..Epoetin delta, unlike recombinant erythropoietins, is produced in a human cell line and therefore has a human-type glycosylation profile...
  12. ncbi request reprint A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder
    Robert L Findling
    University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    J Clin Psychiatry 69:149-59. 2008
    ..To evaluate the efficacy and safety of methylphenidate transdermal system compared with placebo, using osmotic-release oral system (OROS) methylphenidate as a reference therapy...
  13. ncbi request reprint Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients
    Jonathan T C Kwan
    S W Thames Renal and Transplantation Unit, Epsom and St Helier University Hospitals NHS Trust, St Helier Hospital, Carshalton, Surrey, UK
    Curr Med Res Opin 23:307-11. 2007
    ..To demonstrate safety and efficacy of epoetin delta for the management of anaemia in predialysis patients with chronic kidney disease (CKD)...
  14. ncbi request reprint Epoetin delta is effective for the management of anaemia associated with chronic kidney disease
    Bruce S Spinowitz
    Curr Med Res Opin 22:2507-13. 2006
    ..Adverse events occurred at frequencies expected for this patient group. CONCLUSIONS: Epoetin delta was effective in increasing haemoglobin levels in patients with baseline haemoglobin of < 10 g/dL...
  15. ncbi request reprint Epoetin delta is effective for the management of anaemia associated with chronic kidney disease
    Bruce S Spinowitz
    Department of Nephrology, New York Hospital Queens and Cornell University Medical Center, New York, NY, USA
    Curr Med Res Opin 22:2507-13. 2006
    ..To demonstrate the efficacy and safety of epoetin delta for the treatment of anaemia in dialysis patients with chronic kidney disease (CKD)...
  16. doi request reprint Letter regarding 'Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate'
    Michael D L Smyth
    Kidney Int 74:536; author reply 536-7. 2008